Magna ease bioprosthetic aortic valve: mid-term haemodynamic outcomes in 1126 patients

Abstract

Magna Ease AVR maintained low mean transprosthetic gradients throughout mid-term evaluation and was associated with excellent overall survival and freedom from reoperation at nine years post implantation.